NCT00103194View on ClinicalTrials.gov

Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Recurrent Prostate CancerStage I Prostate CancerStage IIA Prostate CancerStage IIB Prostate CancerStage III Prostate Cancer
Interventions
DRUG

lapatinib ditosylate

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

19103

ECOG-ACRIN Cancer Research Group, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00103194 - Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer | Biotech Hunter | Biotech Hunter